Bluejay Therapeutics’ Brelovitug (BJT-778) Monotherapy Achieved 100% Virologic Response and up to 82% Combined Endpoint of Virologic Response and ALT Normalization at Week 48 ...

All brelovitug dose regimens studied were well tolerated Results will be presented at The Liver Meeting® 2025 of AASLDAdditional preclinical data ...